| Drug ID: | Drug52 |
|---|---|
| Drug Name: | Iron |
| CID: | 23925 |
| DrugBank ID: | DB01592 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | NO |
| Other Approved: | YES |
| Identifier: | NCT01017614, , NCT03441893 |
| Molecular Formula: | Fe |
| Molecular Weight: | 55.84 g/mol |
| Isomeric SMILES: | [Fe] |
| Synonyms: | IRON; 7439-89-6; Iron, elemental; Ferrum; Iron powder; Remko; Armco iron; Ferrovac E; Ancor B; hierro |
| Phase 0: | 4 |
| Phase 1: | 19 |
| Phase 2: | 46 |
| Phase 3: | 81 |
| Phase 4: | 92 |
| Description: | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt472 | 23925 | Iron | 3040 | HBA2 | Homo sapiens (human) | Activator | |
| dt473 | 23925 | Iron | 7037 | TFRC | Homo sapiens (human) | 16564538 | None |
| dt474 | 23925 | Iron | 54583 | EGLN1 | Homo sapiens (human) | 16649251 | None |
| dt475 | 23925 | Iron | 55869 | HDAC8 | Homo sapiens (human) | 16681389 | Cofactor |
| dt476 | 23925 | Iron | 51327 | AHSP | Homo sapiens (human) | 16901899 | None |
| dt477 | 23925 | Iron | 2395 | FXN | Homo sapiens (human) | 16911956 | None |
| dt478 | 23925 | Iron | 2495 | FTH1 | Homo sapiens (human) | 17070541 | None |
| dt479 | 23925 | Iron | 2237 | FEN1 | Homo sapiens (human) | 20622253 | None |
| dt480 | 23925 | Iron | 79661 | NEIL1 | Homo sapiens (human) | 20622253 | None |
| dt481 | 23925 | Iron | 252969 | NEIL2 | Homo sapiens (human) | 20622253 | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05581420 | Oral Versus Intravenous Iron in IBD Patients With Anti-inflammatory Therapy. | NA | UNKNOWN | Leiden University Medical Center | Inflammatory Bowel Diseases | DRUG: Ferrous fumarate|DRUG: MonoFer | Details |
| NCT05456932 | Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease | PHASE4 | UNKNOWN | Leiden University Medical Center | Inflammatory Bowel Diseases|Iron-deficiency|Iron … | DRUG: Intravenous iron|DRUG: Ferric maltol|DRUG: … | Details |
| NCT07141238 | Microplastic Analysis in Pediatric Inflammatory Bowel Disease | NULL | RECRUITING | Medical University of Gdansk | Crohn Disease|Pediatric Inflammatory Bowel Diseas… | OTHER: Environmental microplastic exposure | Details |
| NCT05225545 | Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis | PHASE3 | UNKNOWN | American University of Beirut Medical Center | Anemia, Iron Deficiency|Ulcerative Colitis | DRUG: Sucrosomial Iron|DRUG: Oral Iron | Details |
| NCT05176795 | Host-microbiota-environment Interactions | NULL | TERMINATED | University Hospital, Clermont-Ferrand | Juvenile Idiopathic Arthritis|Diabetes type1|Infl… | OTHER: Stool sample | Details |
| NCT04960826 | Study of an Environmental Risk Factor in Crohn's Disease | NULL | RECRUITING | University Hospital, Lille | Inflammatory Bowel Diseases | None | Details |
| NCT04587141 | Clinical Burden of Anemia in Inflammatory Bowel Disease: Therapeutic Trial | PHASE3 | UNKNOWN | Fondazione IRCCS Policlinico San Matteo di Pavia | Iron Deficiency Anemia|Inflammatory Bowel Diseases | DRUG: Sucrosomial iron|DRUG: Ferric Gluconate|DRU… | Details |
| NCT04565821 | Feasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe | NA | ACTIVE_NOT_RECRUITING | Massachusetts General Hospital | Inflammatory Disease|Permeability; Increased|Croh… | DEVICE: IPD Probe via TNIT | Details |
| NCT04318405 | Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE). | NULL | COMPLETED | Pierre Fabre Pharma AG | Iron-Deficiency Anemia|Iron-Deficiency | DRUG: Iron isomaltoside 1000 | Details |
| NCT07380022 | Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB Defense and Goodphyte Immunity in Adults With Chronic Diseases. | NA | RECRUITING | University of Thessaly | IBD|Hypertension (HTN)|Multiple Sclerosis|Anemia|… | DIETARY_SUPPLEMENT: Dietary supplement interventi… | Details |
| NCT04123990 | Study of the Prevalence of Iron Deficiency in Patients With Chronic Inflammatory Bowel Disease | NA | UNKNOWN | VIFORFRANCE | Intestinal Disease | DIAGNOSTIC_TEST: Iron status testing | Details |
| NCT03872622 | Intestinal Response Patterns to Microbial Signals | NA | COMPLETED | Sheba Medical Center | CD - Crohn's Disease | OTHER: Blood tests, intestinal biopsies, stool sa… | Details |
| NCT03466983 | A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease | PHASE4 | COMPLETED | Pharmacosmos A/S | IBD | DRUG: Iron Isomaltoside|DRUG: Ferric Carboxymalto… | Details |
| NCT03457571 | Clinical Observational Study: IBD Patients With Restless-legs-syndrome and Iron Deficiency Syndrome | NULL | COMPLETED | Charite University, Berlin, Germany | Inflammatory Bowel Diseases|Restless Legs Syndrom… | None | Details |
| NCT03376230 | Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease | NULL | TERMINATED | University Hospital, Lille | Inflammatory Bowel Diseases | OTHER: Collect of blood, urines, and intestinal b… | Details |
| NCT03282903 | The PRognostic Effect of Environmental Factors in Crohn's and Colitis | NULL | COMPLETED | University of Edinburgh | Inflammatory Bowel Diseases|Crohn Disease|Ulcerat… | None | Details |
| NCT03247816 | Feraccru® Real World Effectiveness Study in Hospital Practice ( FRESH ) | NULL | COMPLETED | Shield Therapeutics | Anemia, Iron Deficiency|Inflammatory Bowel Diseas… | None | Details |
| NCT03136419 | Microbiota and Immune microEnvironment in Pouchitis | NA | UNKNOWN | University of Padova | Pouchitis|Ulcerative Colitis|Ileal Pouch | DIETARY_SUPPLEMENT: Lactobacillus casei DG|DIETAR… | Details |
| NCT02965209 | European Novel Motorized Spiral Endoscopy Trial | NA | COMPLETED | Evangelisches Krankenhaus Düsseldorf | Disorder of Small Intestine|Gastrointestinal Hemo… | PROCEDURE: motorized spiral enteroscopy | Details |
| NCT02774057 | Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD | PHASE4 | UNKNOWN | American University of Beirut Medical Center | Iron Deficiency Anemia|Inflammatory Bowel Disease | DRUG: Captafer®|DRUG: Iron Sulfate | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| 1.0 | Crohn's disease | An intestinal disease that involves inflammation located_in intestine. | disease of anatomical entity gastrointestinal system disease, intestinal disease, inflammatory bowel disease | Obiltoxaximab; Budesonide; Hydrocortisone acetate; Sulfasalazine; Ursodeoxycholic acid; Pegunigalsidase alfa; Imiglucerase; Bictegravir; Taliglucerase alfa; Etelcalcetide; Cimetidine; Desonide | Crohn's disease is a relapsing systemic inflammatory diseas… | Details |
| 2.0 | ulcerative colitis | A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. | disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract | Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib | No abstract available | Details |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
| S08 | Strengthening barrier function | Modulation of barrier function | phosphatidylcholine (lecithin); imiquimod; mongersen | Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negat… | Details |
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
kLDM: Inferring Multiple Metagenomic Association Networks Based on the Variatio…
PMID: 33607296
Year: 2021
Relationship Type:
Association
Score: 9.5
Identification of significant biological relationships or patterns is central to many metagenomic studies. Methods that estimate association networks…
Questions and answers on iron deficiency treatment selection and the use of int…
PMID: 33426933
Year: 2021
Relationship Type:
Treatment
Score: 9.5
Iron deficiency is a common cause of morbidity and can arise as a consequence or complication from many diseases. The use of intravenous iron has inc…
Hydrogen sulfide toxicity in the gut environment: Meta-analysis of sulfate-redu…
PMID: 33318866
Year: 2020
Relationship Type:
Adverse Effect
Score: 9.5
BACKGROUND: Hydrogen sulfide is the final product of sulfate-reducing bacteria metabolism. Its high concentration in the gut can affect adversely bow…
Iron deficiency, depression, and fatigue in inflammatory bowel diseases
PMID: 33291175
Year: 2020
Relationship Type:
Treatment
Score: 9.5
Iron deficiency (ID) caused by blood loss and/or reduced iron absorption is a serious problem influencing health in inflammatory bowel disease (IBD)…
Safety profile of intravenous iron in inflammatory bowel disease: an up-to-date…
PMID: 33267572
Year: 2022
Relationship Type:
Treatment
Score: 9.5
Inflammatory bowel disease (IBD) is characterized by chronic and relapsing inflammatory disorder of the intestine. IBD is associated with complex p…
Freshwater zooplankton metapopulations and metacommunities respond differently …
PMID: 33067865
Year: 2021
Relationship Type:
Treatment
Score: 9.5
An intestinal epithelium model able to produce mucus was developed to provide an environment suitable for testing the therapeutic activity of gut ba…
Iron Deficiency Anemia-Induced Lymphocytopenia in a Young Female
PMID: 32884520
Year: 2020
Relationship Type:
Treatment
Score: 9.5
Iron deficiency anemia is the most common type of anemia, and it occurs when the human body does not have enough of the mineral iron (https://www.hea…
A rare case of parental iron-induced persistent hypophosphatemia
PMID: 32850057
Year: 2020
Relationship Type:
Adverse Effect
Score: 9.5
We report a case of an African American woman who presented with fatigue, generalized weakness, and hypophosphatemia in the setting of a recent hospi…
Gastroenterologist-Lead Management of Iron Deficiency Anemia in Inflammatory Bo…
PMID: 32743547
Year: 2020
Relationship Type:
Association
Score: 9.5
BACKGROUND: Early life exposures impact immune system development and therefore the risk of immune-mediated diseases, including inflammatory bowel d…
TIAM2S Mediates Serotonin Homeostasis and Provokes a Pro-Inflammatory Immune Mi…
PMID: 32650570
Year: 2020
Relationship Type:
Association
Score: 9.5
The short isoform of human TIAM2 has been shown to promote proliferation and invasion in various cancer cells. However, the roles of TIAM2S in immune…
Inflammatory Bowel Diseases: Host-Microbial-Environmental Interactions in Dysbi…
PMID: 32397606
Year: 2020
Relationship Type:
Adverse Effect
Score: 9.5
Crohn's Disease (CD) and Ulcerative Colitis (UC) are world-wide health problems in which intestinal dysbiosis or adverse functional changes in the mi…
Treatment of iron deficiency anemia with liposomal iron in inflammatory bowel d…
PMID: 32367457
Year: 2020
Relationship Type:
Treatment
Score: 9.5
Background Anemia is a clinical condition frequently seen in patients with inflammatory bowel disease, which is responsible for a significant loss of…
CD30L/CD30 signaling regulates the formation of the tumor immune microenvironme…
PMID: 32353687
Year: 2020
Relationship Type:
Treatment
Score: 9.5
Inflammatory bowel disease is one of the major causes of colitis-associated colon cancer (CAC). Therefore, it is necessary to explore new therapies t…
Crohn's disease and environmental contamination: Current challenges and perspec…
PMID: 32325248
Year: 2020
Relationship Type:
Mechanism
Score: 9.5
Although the incidence of Crohn's disease has increased worldwide over the past 30 years, the disorder's exact causes and physiological mechanisms ha…
Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency
PMID: 32297281
Year: 2020
Relationship Type:
Treatment
Score: 9.5
Iron deficiency and iron-deficiency anemia are associated with increased morbidity and mortality in a wide range of conditions. In many patient popul…
Dendritic cell-derived hepcidin sequesters iron from the microbiota to promote …
PMID: 32273468
Year: 2020
Relationship Type:
Mechanism
Score: 9.5
Bleeding and altered iron distribution occur in multiple gastrointestinal diseases, but the importance and regulation of these changes remain unclear…
Androgen deprivation therapy and the risk of iron-deficiency anaemia among pati…
PMID: 32213519
Year: 2020
Relationship Type:
Treatment
Score: 9.5
OBJECTIVES: The administration of androgen deprivation therapy (ADT) to patients with metastatic prostate cancer might be associated with some advers…
Relative importance of isolation-by-environment and other determinants of gene …
PMID: 32187652
Year: 2020
Relationship Type:
Association
Score: 9.5
Inflammatory Bowel Disease (IBD) is idiopathic, chronic and affects the gastrointestinal tract. It results from the association of genetic, environ…
Iron deficiency-induced thrombocytosis increases thrombotic tendency in rats
PMID: 32079699
Year: 2021
Relationship Type:
Treatment
Score: 9.5
Iron deficiency (ID) is globally prevalent, and apart from anemia is associated with thrombocytosis. While considered benign, studies linking thrombo…
Anemia and iron deficiency in Crohn's disease
PMID: 32077335
Year: 2020
Relationship Type:
Treatment
Score: 9.5
Introduction: Anemia is a common extraintestinal complication of Crohn's disease (CD) mainly caused by iron deficiency, that affects the quality of l…